November 1, 2004
View Archives Issues
Physicians increasingly are aware of the need to provide prophylaxis against venous thrombosis for the medically ill patient in the hospital environment. This article attempts to separate the fact from fiction regarding VTE prophylaxis.
Merck announced on September 30th that it is voluntarily withdrawing rofecoxib (Vioxx) from the worldwide market.